"BDAZ - If there is statistical significance in a sub group ABL+Crestor or ABL+Lipitor but not the entire trial could there still be a marketable product? (eg. ABL+Crestor 57% RRR and ABL+Lipitor 15% RRR, entire trial 26% RRR)."
Yes, we've pondered that before and I don't know the answer. Sure, Resverlogix could submit MAA and NDA to EMA and FDA, respectively, for a subgroup, but no guarantee that the MAA or NDA would be approved. I hope it would, but I do not know.
BearDownAZÂ
